A small clinical trial for an immunodeficiency disease provides a new way to think about gene therapy (pages 401–409).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cavazzana-Calvo, M. et al. Science 288, 669–672 (2000).
Aiuti, A. et al. Science 296, 2410–2413 (2002).
Gaspar, H.B. et al. Lancet 364, 2181–2187 (2004).
Hacein-Bey-Abina, S. et al. Science 302, 415–419 (2003).
Ott, M. et al. Nat. Med. 12, 401–409 (2006)
Malech, H.L. et al. Proc. Natl. Acad. Sci. USA 94, 12133–12138 (1997).
Baum, C., Hegewisch-Becker, S., Eckert, H.G., Stocking, C. & Ostertag, W. J. Virol. 69, 7541–7547 (1995).
Buonamici, S., Chakraborty, S., Senyuk, V. & Nucifora, G. Blood Cells Mol. Dis. 31, 206–212 (2003).
Du, Y., Jenkins, N.A. & Copeland, N.G. Blood 106, 3932–3939 (2005).
Calmels, B. et al. Blood 106, 2530–2533 (2005).
Kustikova, O. et al. Science 308, 1171–1174 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Naldini, L. Inserting optimism into gene therapy. Nat Med 12, 386–388 (2006). https://doi.org/10.1038/nm0406-386
Issue Date:
DOI: https://doi.org/10.1038/nm0406-386